The work in her lab has led to the discovery of the cardioprotective agents and the elucidation of their novel mechanism of action. Her expertise in cardioprotection and autophagy is recognized on a national and international level.
Dr. Gottlieb is also an entrepreneur, having started a biotechnology company called Radical Therapeutix, to develop drugs to mitigate the damage to the heart during myocardial infarction. Dr. Gottlieb received her B.S. and M.D. degrees from Johns Hopkins University.